| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
As a PROTAC linker, 12-Amino-1-dodecanol does not have direct biological targets. Its role is to serve as a chemical building block for the synthesis of PROTAC molecules. The primary amine and primary alcohol provide orthogonal functional groups for selective conjugation to target protein ligands and E3 ubiquitin ligase ligands. The 12-carbon alkyl chain provides an extended, flexible spacer length. According to reported literature, ideal linker lengths for PROTACs range from 12 to over 20 carbons, making this dodecyl chain well-suited for optimal PROTAC activity and ternary complex formation.
|
|---|---|
| ln Vitro |
PROTAC contains two distinct ligands linked by a single linker: one is the ligand for the E109 ubiquitin ligase, and the other is the ligand for the target protein. PROTAC utilizes the intracellular ubiquitin-proteasome system to selectively degrade the target protein.
This compound does not have direct in vitro biological activity as it is a chemical linker. In PROTAC development, the compound is first selectively functionalized at the alcohol and amine groups to attach target protein ligands and E3 ligase ligands. The resulting PROTAC is then evaluated in cellular assays for target protein degradation. The long, flexible 12-carbon linker allows the PROTAC to reach across the ternary complex interface and effectively position the target protein and E3 ligase for ubiquitination. |
| ln Vivo |
No direct in vivo activity has been reported for 12-Amino-1-dodecanol alone. For PROTACs synthesized using this long-chain alkyl linker, in vivo efficacy is evaluated in xenograft mouse models. The 12-carbon alkyl chain provides optimal flexibility and length for ternary complex formation in the crowded cellular environment, potentially enhancing degradation potency and selectivity. PROTACs with this linker are administered via intraperitoneal or intravenous injection, and target protein degradation in tumor tissues is assessed by western blotting.
|
| Enzyme Assay |
No specific enzyme/receptor binding protocols have been established for this compound. Standard synthetic protocols for using 12-Amino-1-dodecanol in PROTAC synthesis involve selective conjugation at the amine and alcohol groups. The primary alcohol can be activated via conversion to a tosylate or mesylate for nucleophilic substitution, or oxidized to an aldehyde or carboxylic acid for reductive amination or amide coupling. The primary amine can be reacted with carboxylic acids using amide coupling reagents such as HATU, EDC, or DCC. Alternatively, the amine can be protected (e.g., with Boc or Fmoc) to allow selective functionalization of the alcohol first, followed by deprotection and conjugation at the amine. Products are purified by column chromatography or preparative HPLC.
|
| Cell Assay |
12-Amino-1-dodecanol is not evaluated in cellular assays directly. For cellular evaluation of PROTACs synthesized using this long-chain alkyl linker, standard protocols involve culturing cancer cell lines (e.g., HEK293, HeLa, MCF-7) in DMEM or RPMI-1640 with 10% FBS at 37degC in 5% CO2. Cells are seeded in 12- or 96-well plates at appropriate densities and allowed to attach overnight. PROTAC is added at concentrations ranging from 0.1 nM to 10 uM for 4-72 hours. Target protein degradation is assessed by western blotting of cell lysates using specific primary antibodies. Cell viability is measured using MTT or CellTiter-Glo assays. All conditions are tested in triplicate for statistical reliability.
|
| Animal Protocol |
For in vivo studies using PROTACs synthesized with 12-Amino-1-dodecanol, standard animal protocols involve xenograft models in immunodeficient mice (nude or NSG mice, 6-8 weeks old, 18-22 g). Approximately 5×10⁶ cancer cells are injected subcutaneously. When tumors reach ~150-200 mm3, mice are randomized into treatment groups (n=5-10 per group). PROTAC is administered intraperitoneally at doses of 1-50 mg/kg in formulation vehicles such as 10% DMSO, 40% PEG300, 5% Tween 80, 45% saline. Tumor volumes are measured every 2-3 days using digital calipers. Body weights are monitored as a toxicity indicator. At study termination, tumors are excised, weighed, and processed for target protein analysis by western blotting. Blood may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
No direct pharmacokinetic studies have been published for 12-Amino-1-dodecanol. Computed properties include molecular formula C12H27NO, molecular weight 201.35 g/mol. The compound has a predicted logP of approximately 3.0-3.5, indicating high lipophilicity due to the long 12-carbon alkyl chain. This high lipophilicity can enhance membrane permeability but may also lead to poor aqueous solubility. For PROTACs incorporating this linker, the pharmacokinetic properties are determined by the overall structure of the complete PROTAC molecule. The 12-carbon linker length is within the reported optimal range of 12 to over 20 carbons for PROTAC activity.
|
| Toxicity/Toxicokinetics |
According to safety data sheets, 12-Amino-1-dodecanol should be handled with standard laboratory precautions. The compound may cause skin and eye irritation. It should be stored at room temperature in a cool, dry, dark place (recommended <15degC). Avoid inhalation, ingestion, and contact with skin and eyes. Wear protective gloves, safety goggles, and a lab coat. Work in a well-ventilated fume hood. The compound is for research use only and not for human therapeutic applications.
|
| Additional Infomation |
12-Amino-1-dodecanol is a PROTAC linker featuring a 12-carbon linear alkyl chain with orthogonal amino and alcohol functional groups. This linker is also known as 12-aminododecan-1-ol. The 12-carbon chain length is within the reported optimal linker length range for PROTACs (12 to over 20 carbons), providing the flexibility and reach necessary for effective ternary complex formation between the target protein, PROTAC, and E3 ubiquitin ligase. The orthogonal functionalities allow for modular assembly of PROTACs through selective conjugation chemistries. This product is used in PROTAC research for targeted protein degradation and is for research use only with no approved clinical applications.
|
| Molecular Formula |
C12H27NO
|
|---|---|
| Molecular Weight |
201.35
|
| Exact Mass |
201.209
|
| CAS # |
67107-87-3
|
| PubChem CID |
5182020
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
14
|
| Complexity |
96.3
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCCCCCO)CCCCCN
|
| InChi Key |
IIWXYWWVCBRBCJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H27NO/c13-11-9-7-5-3-1-2-4-6-8-10-12-14/h14H,1-13H2
|
| Chemical Name |
12-aminododecan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9665 mL | 24.8324 mL | 49.6648 mL | |
| 5 mM | 0.9933 mL | 4.9665 mL | 9.9330 mL | |
| 10 mM | 0.4966 mL | 2.4832 mL | 4.9665 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
